{
    "data": [
        {
            "id": "4603806",
            "type": "article",
            "attributes": {
                "publishOn": "2023-05-12T16:15:31-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1199671867/image_1199671867.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A Look",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103980",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "455648",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "585375",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4603806-equillium-negative-ev-biotech-compelling-programs-cash-till-at-least-2025-worth-look"
            }
        }
    ]
}